At The University of Chicago Medicine, physicians treating breast cancer patients will have a new tool to help them create personalized treatment plans for their patients. Chicago-based Tempus is collaborating with the university to provide specific genetic information to doctors, which will allow them to make real-time treatment decisions based on an analysis of molecular and clinical data. Tempus has already collaborated with the Mayo Clinic, Penn Medicine and several other hospitals, giving them access to DNA and RNA genomic sequencing and a machine-learning platform to utilize the results.

Already familiar with big data from his other business ventures,Eric Lefkofsky saw that there was an enormous amount of data available to physicians treating cancers, but no easy way for them to analyze the information. In his entrepreneurial career, Lefkofsky co-founded Groupon, Uptake Technologies, Mediaocean and Echo Global Logistics, each business each relied on big data to revolutionize their respective industries. Lefkofsky wrote Accelerated Disruption: Understanding the True Speed of Innovation, where he explains his success by telling potential entrepreneurs how to take a disruptive idea that changes an industry and get it to market quickly by utilizing technology. Lefkofsky teaches these same techniques his students as an adjunct professor at the University of Chicago.

Not content to have Groupon as his legacy, Lefkofsky started Tempus to fill a need to help physicians take advantage of the case histories of patients with similar genetic make-ups, so that they could adjust their treatment plans accordingly. While Lefkofsky graduated from the University of Michigan Law School, his real talent is discovering who to advance any industry by mining data and them compiling it into a useful platform. With Tempus, Lefkofsky’s business and philanthropy are aligned as the Lefkofsky Family Foundation contributes significant amounts of money to organizations such as the Leukemia & Lymphoma Society, the Memorial Sloan-Kettering Cancer Center and the Pancreatic Cancer Action Network.